Alexander Egle

Alexander Egle is an Associate Professor and Department Chair at the University of Salzburg's Faculty of Medicine, leading the Department of Internal Medicine III. His research focuses on hematological malignancies, including chronic lymphocytic leukemia (CLL), multiple myeloma, and oncologic therapeutics. He has authored over 230 publications and led multiple research projects on topics like MTOR signaling in CLL and clinical trials for cancer treatments. Egle’s work emphasizes translational medicine, integrating molecular biology with clinical outcomes. He actively collaborates on international studies, such as meta-analyses for immunocompromised patients and quality-of-life assessments in cancer therapies.

• Education: Not explicitly stated in text, inferred through professional roles.

Research Interests: Hematology, oncology, clonal evolution in cancers, and translational therapies. His studies explore mechanisms of drug resistance in CLL and optimize treatments for multiple myeloma patients. He also investigates circulating tumor DNA and cell-free DNA applications in oncology monitoring.

Recent articles highlight his contributions to immunomodulatory therapies for immunocompromised patients, MTOR pathway compensatory mechanisms in CLL, and quality-of-life analyses in myeloma treatments. These studies reflect his dual focus on basic science and clinical application.

As Principal Investigator (PI), he led projects on Bcl-2 family proteins, single-cell mass spectrometry in CLL phenotyping, and cell-free DNA in head and neck cancer monitoring. These efforts underscore his leadership in advancing diagnostic and therapeutic strategies in oncology.

Egle’s collaborations include FWF project grants and international studies, demonstrating his role in fostering global research networks.